1921
Volume 86, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Yellow fever vaccine provides long-lasting immunity. Rare serious adverse events after vaccination include neurologic or viscerotropic syndromes or anaphylaxis. We conducted a systematic review of adverse events associated with yellow fever vaccination in vulnerable populations. Nine electronic bibliographic databases and reference lists of included articles were searched. Electronic databases identified 2,415 abstracts for review, and 32 abstracts were included in this review. We identified nine studies of adverse events in infants and children, eight studies of adverse events in pregnant women, nine studies of adverse events in human immunodeficiency virus-positive patients, five studies of adverse events in persons 60 years and older, and one study of adverse events in individuals taking immunosuppressive medications. Two case studies of maternal–neonate transmission resulted in serious adverse events, and the five passive surveillance databases identified very small numbers of cases of yellow fever vaccine-associated viscerotropic disease, yellow fever vaccine-associated neurotropic disease, and anaphylaxis in persons ≥ 60 years. No other serious adverse events were identified in the other studies of vulnerable groups.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.11-0525
2012-02-01
2017-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/86/2/359.html?itemId=/content/journals/10.4269/ajtmh.2012.11-0525&mimeType=html&fmt=ahah

References

  1. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC), 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep Recommendations. July 30, 2010/Vol 59/No. RR-7, 127.
  2. Monath TP, Cetron MS, Teuwen DE, SA Plotkin, WA Orenstein, PA Offit, , 2008. Yellow fever vaccine. , eds. Vaccines, 5th ed. Philadelphia, PA: W.B. Saunders, 9591055.
  3. WHO Emerging and Other Communicable Diseases, 1998. District Guidelines for Yellow Fever Surveillance. Geneva, Switzerland: World Health Organization.
  4. WHO Division of Epidemiological Surveillance and Health Situation Trend Assessment, 1992. Global Health Situation and Projections—Estimates. Geneva, Switzerland: World Health Organization.
  5. Rogers DJ, Wilson AJ, Hay SI, Graham AJ, , 2006. The global distribution of yellow fever and dengue. Adv Parasitol 62: 181220.[Crossref]
  6. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE, , 2007. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 27582765.[Crossref]
  7. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, Monath TP, , 2004. High fidelity of yellow fever virus RNA polymerase. J Virol 78: 10321038.[Crossref]
  8. World Health Organization, 2011. International Travel and Health. Available at: http://www.who.int/ith/chapters/en/index.html. Accessed October 9, 2011.
  9. Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, Gidudu J, Katikaneni L, Khuri-Bulos N, Oleske J, Tapianen T, Wiznitzer M, Brighton Collaboration Encephalitis Working Group, 2007. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 25: 57715792.[Crossref]
  10. Rüggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkela M, Nell P, Pool V, Simpson N, Brighton Collaboration Analphylaxis Working Group, 2007. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 25: 56755684.[Crossref]
  11. Bae HG, Domingo C, Tenorio A, de Ory F, Munoz J, Weber P, Teuwen DE, Niedrig M, , 2008. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 197: 15771584.[Crossref]
  12. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS, The Yellow Fever Vaccine Safety Working Group, 2005. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 32563263.[Crossref]
  13. Rosner BA, , 1990. Fundamentals of Biostatistics, 3rd ed. Boston, MA: PWS-KENT, 9495.
  14. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB, , 2008. Adverse event reports following yellow fever vaccination. Vaccine 26: 60776082.[Crossref]
  15. Lawrence GL, Burgess MA, Kass RB, , 2004. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 28: 244248.
  16. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS, GeoSentinel Yellow Fever Working Group, 2001. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7: 945951.[Crossref]
  17. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, Bedford P, , 2005. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1: 207214.[Crossref]
  18. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP, , 2005. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med 72: 189197.
  19. Lhuillier M, Mazzariol MJ, Zadi S, Le CN, Bentejac MC, Adamowicz L, Marie FN, Fritzell B, , 1989. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 17: 915.[Crossref]
  20. Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK, , 2001. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ 79: 10561059.
  21. Soula G, Sylla A, Pichard E, Kodio B, Bentejac MC, Teulieres L, , Saliou P, 1991. Ėtude d'un nouveau vaccin combiné contre la fièvre jaune et la rougeole chez les enfants agés de 6 au 24 mois au Mali. Bull Soc Pathol Exot 84: 885897.
  22. Mouchon D, Pignon D, Vicens R, Tu HT, Tekaia F, Teulieres L, , Garrigue G, 1990. Ėtude de la vaccination combinée rougeole-fièvre jaune chez l'enfant africain agé de 6 à 10 mois. Bull Soc Pathol Exot 83: 537551.
  23. Cannon D, , 1955. Encephalitis after yellow fever vaccination. BMJ 1: 1090.
  24. Couto AM, , 2010. Transmission of yellow fever vaccine virus through breast feeding—Brazil 2009. MMWR Morb Mortal Wkly Rep 59: 130132.
  25. Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B, , 2011. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183: E243E245.[Crossref]
  26. Global Advisory Committee on Vaccine Safety, 2010. Wkly Epidemiol Rec 85: 285291.
  27. Cavalcanti DP, Salomão MA, Lopez-Camelo J, Pessoto MA, Campinas Group of Yellow Fever Immunization during Pregnancy, 2007. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12: 833837.[Crossref]
  28. Nasidi A, Monath TP, Vandenberg J, Tomori O, Calisher CH, Hurtgen X, Munube GR, Sorungbe AO, Okafor GC, Wali S, , 1993. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 87: 337339.[Crossref]
  29. Papaiordanou P, Sato H, Freire M, Yamamura A, Gouveia F, Amaral E, , 2001. Yellow fever vaccination during pregnancy. Abs Intersci Conf Antimicrob Agents Chemother 41: Abstract G-1571, page 275.
  30. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, Campinas Group on Yellow Fever Immunization During Pregnancy, 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 14211426.[Crossref]
  31. D'Acremont V, Tremblay S, Genton B, , 2008. Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: a longitudinal study. J Travel Med 15: 7781.[Crossref]
  32. Nishioka Sde A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL, , 1998. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 3: 2933.[Crossref]
  33. Robert E, Vial T, Schaefer C, Arnon J, Reuvers M, , 1999. Exposure to yellow fever vaccine in early pregnancy. Vaccine 17: 283285.[Crossref]
  34. Tsai TF, Paul R, Lynberg MC, Letson GW, , 1993. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 168: 15201523.[Crossref]
  35. Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, Furrer H, , 2009. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48: 659666.[Crossref]
  36. Goujon C, Tohr M, Feuillie V, Coulaud P, Dupont B, Sansonetti P, , 1995. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. J Travel Med 2: 145.
  37. Pacanowski J, Campa P, Dabrowska M, Lacombe K, , 2008. Antibody response and safety of yellow fever vaccination in HIV infected patients. Proceedings of the 48th Annual International Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.
  38. Receveur MC, Thiébaut R, Vedy S, Malvy D, Mercié P, Le Bras M, , 2000. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 31: E7E8.[Crossref]
  39. Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, Poved JD, Michelet C, , 2004. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18: 825827.[Crossref]
  40. Pistone T, Verdière C-H, Receveur M-C, Ezzedine K, Lafon ME, Malvy D, , 2007. Immunogénicité et tolérance du vaccin amaril chez le voyageur vivant avec le VIH, France, 2005. Bull Epidemiologique Hebdomadaire 25/26: 238240.
  41. Pistone T, Verdière C-H, Receveur M-C, Ezzedine K, Lafon ME, Malvy D, , 2010. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 8: 461466.[Crossref]
  42. Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S, , 2008. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 22: 6570.[Crossref]
  43. Kengsakul K, Sathirapongsasuti K, Punyagupta S, , 2002. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131134.
  44. Veit O, Hatz C, Niedrig M, Furrer H, , 2010. Yellow fever vaccination in HIV-infected patients. HIV Ther 4: 1726.[Crossref]
  45. da Mota LMH, Oliveira ACV, Lima RAC, dos Santos-Neto LL, Tauil PL, , 2009. Vacinação contra febre amarela em pacientes com diagnósticos de doenças reumáticas, em uso de immunosuppressores. Rev Soc Bras Med Trop 42: 2327.[Crossref]
  46. Kelso JM, Mootrey GT, Tsai TF, , 1999. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999: 698701.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.11-0525
Loading
/content/journals/10.4269/ajtmh.2012.11-0525
Loading

Data & Media loading...

  • Received : 13 Aug 2011
  • Accepted : 22 Oct 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error